Compounds > celecoxib

celecoxib and osu 03012

celecoxib has been researched along with osu 03012 in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's8 (66.67)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Chen, CS; Chen, YR; Chiu, HC; Kapuriya, N; Kulp, SK; Lee, SL; Teng, LJ; Wang, D; Yu, SL1
Brueggemeier, RW; Chen, CS; Chen, CY; Dunn, SE; Pollak, M; Shapiro, CL; Tseng, PH; Wang, YC; Weng, JR; Weng, SC1
Chen, CS; Espinosa, AV; Guerra, M; Kirschner, LS; Kulp, SK; Porchia, LM; Ringel, MD; Saji, M; Shinohara, M; Wang, YC; Zhang, Y1
Chen, TC; Hofman, FM; Louie, SG; Petasis, NA; Schönthal, AH1
Iwamoto, T; Iyoda, T; Kita, S; Yamada, T; Yamamoto, S1
Booth, L; Chen, CS; Cruickshanks, N; Dent, P; Grant, S; Ridder, T1
Liu, J; Lv, W; Qin, CK; Qin, CY; Zhao, Q1
Liu, F; Liu, J; Luo, Z; Wang, M; Zhang, J; Zhang, Z1
Cushion, MT; DiDone, L; Fothergill, AW; Green, J; Halterman, JP; Koselny, K; Krysan, DJ; Patterson, TF; Rappelye, C; Wellington, M; Wiederhold, NP1
Abu Bakar, S; Hassandarvish, P; Jokar, A; Oo, A; Proniuk, S; Zandi, K; Zukiwski, A1
Abdelaziz, D; Abdulrahman, BA; Gilch, S; Jain, S; Lu, L; Proniuk, S; Schatzl, HM; Thapa, S; Zukiwski, A1
Legrand, N; Sobolewski, C1

Reviews

2 review(s) available for celecoxib and osu 03012

ArticleYear
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:2

    Topics: Animals; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2; Drug Evaluation, Preclinical; Humans; Neoplasms; Neovascularization, Pathologic; Pyrazoles; Sulfonamides

2008
Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib.
    Biomolecules, 2021, 07-16, Volume: 11, Issue:7

    Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Cycle; Cyclooxygenase 2 Inhibitors; Humans; Neoplasms; Pyrazoles; Sulfonamides

2021

Other Studies

10 other study(ies) available for celecoxib and osu 03012

ArticleYear
Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.
    Bioorganic & medicinal chemistry, 2012, Aug-01, Volume: 20, Issue:15

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; HT29 Cells; Humans; Injections, Intraperitoneal; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship

2012
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Molecular pharmacology, 2006, Volume: 70, Issue:5

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression; Humans; Phenotype; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptor, ErbB-2; Receptor, IGF Type 1; Sulfonamides; Trastuzumab; Up-Regulation

2006
2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Molecular pharmacology, 2007, Volume: 72, Issue:5

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; p21-Activated Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Sulfonamides; Thyroid Neoplasms

2007
OSU-03012, a novel celecoxib derivative, induces cell swelling and shortens action potential duration in mouse ventricular cells.
    Biomedical research (Tokyo, Japan), 2010, Volume: 31, Issue:6

    Topics: Action Potentials; Adenosine Triphosphate; Animals; Celecoxib; Cell Size; Glyburide; Heart Ventricles; KATP Channels; Male; Membrane Potentials; Mice; Mice, Inbred C57BL; Patch-Clamp Techniques; Pyrazoles; Sulfonamides

2010
OSU-03012 interacts with lapatinib to kill brain cancer cells.
    Cancer biology & therapy, 2012, Volume: 13, Issue:14

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Benzoquinones; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Genes, erbB-1; Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Lipids; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides

2012
OSU-03012, a non-Cox inhibiting celecoxib derivative, induces apoptosis of human esophageal carcinoma cells through a p53/Bax/cytochrome c/caspase-9-dependent pathway.
    Anti-cancer drugs, 2013, Volume: 24, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 9; Celecoxib; Cell Line, Tumor; Cytochromes c; Esophageal Neoplasms; Humans; Pyrazoles; Signal Transduction; Sulfonamides; Tumor Suppressor Protein p53

2013
Celecoxib derivative OSU-03012 inhibits the proliferation and activation of hepatic stellate cells by inducing cell senescence.
    Molecular medicine reports, 2015, Volume: 11, Issue:4

    Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2 Inhibitors; G1 Phase Cell Cycle Checkpoints; Hepatic Stellate Cells; Humans; Pyrazoles; Signal Transduction; Sulfonamides; Up-Regulation

2015
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:12

    Topics: Animals; Antifungal Agents; Candida; Caspofungin; Celecoxib; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Fluconazole; Gene Expression Regulation, Fungal; Lipopeptides; Male; Mice, Inbred Strains; Microbial Sensitivity Tests; Pneumocystis; Pyrazoles; Saccharomyces cerevisiae; Sulfonamides

2016
Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes.
    The Journal of antimicrobial chemotherapy, 2017, 09-01, Volume: 72, Issue:9

    Topics: Animals; Antiviral Agents; Celecoxib; Chlorocebus aethiops; Dengue; Dengue Virus; Drug Discovery; Heat-Shock Proteins; Molecular Docking Simulation; Pyrazoles; Real-Time Polymerase Chain Reaction; RNA, Viral; Serogroup; Sulfonamides; Vero Cells; Virus Replication

2017
The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions.
    Scientific reports, 2017, 12-14, Volume: 7, Issue:1

    Topics: Animals; Autophagy; Celecoxib; Cell Line, Tumor; Mice; Neurons; PrPSc Proteins; Pyrazoles; Sulfonamides

2017